



Date: 23<sup>rd</sup> November, 2024

To,  
The Manager,  
Department of Corporate Services,  
BSE Limited  
P. J. Towers, Dalal Street,  
Fort, Mumbai – 400 001  
BSE Scrip Code: 533573

To,  
The Manager,  
Listing Department,  
National Stock Exchange of India Ltd.  
'Exchange Plaza', Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051  
NSE Symbol: APLLTD

Dear Sir / Madam,

**Sub: US FDA inspection at Alembic Pharmaceuticals Limited' Solid Oral Formulation Facility (F-4) at Jarod.**

We would like to inform the exchange that the United States Food and Drug Administration (US FDA) has conducted an inspection at our Solid Oral Formulation Facility (F-4) located at Jarod from 14<sup>th</sup> November 2024 to 22<sup>nd</sup> November 2024. This was a scheduled GMP inspection. The USFDA issued a Form 483 with five procedural observations.

The Company will provide comprehensive response to US FDA for the observations within the stipulated period.

The Company is committed to maintain the highest quality standards and compliance at all times.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,  
**For Alembic Pharmaceuticals Limited**

**Manisha Saraf**  
**Company Secretary**

**ALEMBIC PHARMACEUTICALS LIMITED**

REGD. OFFICE: ALEMBIC ROAD, VADODARA - 390 003. • TEL: (0265) 2280550, 2280880 • FAX: (0265) 2281229  
Website : [www.alembicpharmaceuticals.com](http://www.alembicpharmaceuticals.com) • E-mail : [alembic@alembic.co.in](mailto:alembic@alembic.co.in) • CIN : L24230GJ2010PLC061123